Radiopharmaceutical CDMO/CMO Services Market Challenges Stem from High Operational Costs and Skilled Workforce Shortages

Radiopharmaceutical CDMO/CMO Services Market Size is valued at USD 2.9 Billion in 2024 and is predicted to reach USD 7.0 Billion by the year 2034 at a 9.2% CAGR during the forecast period for 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2472

Latest Drivers Restraint and Opportunities Market Snapshot:
Key factors influencing the global radiopharmaceutical CDMO/CMO services market are:
• Growing prevalence of cancer
• Growing interest in personalized treatment
• Technological advancements
The following are the primary obstacles to the radiopharmaceutical CDMO/CMO services market's expansion:
• High cost
• Inadequate infrastructure
• Shortages of skilled workers
Future expansion opportunities for the global radiopharmaceutical CDMO/CMO services market include:
• Growing use of nuclear therapy in underdeveloped nations
• Increasing investments in research and development
• Increased partnership with pharmaceutical industries
Key Industry Insights & Findings from the report:
• The market is growing rapidly due to supportive government initiatives and technological advancements.
• The market for radiopharmaceutical CDMO/CMO services is driven by the increasing incidence of cancer and pharmaceutical firms outsourcing manufacturing to save costs and comply with regulations.
• North America dominated the market and accounted for a revenue share of global revenue in 2023.
• High costs and lack of infrastructure are major issues impeding industry expansion.

Market Analysis:
The radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) services market is experiencing significant growth, driven by the increasing prevalence of cardiovascular diseases and cancer, alongside rising demand for nuclear-based therapies and advancements in radiopharmaceutical technologies.

Market expansion is further supported by strong governmental initiatives, growing investments in research and development, and the widespread integration of advanced medical imaging applications. In addition, the increasing emphasis on personalized medicine and the rising demand for tailored therapeutic solutions are contributing to the accelerated adoption of radiopharmaceutical contract development and manufacturing services.

List of Prominent Players in the Radiopharmaceutical CDMO/CMO Services Market:
• Minerva Imaging
• Evergreen Theragnostics, Inc.
• NMR (NorthStar Medical Radioisotopes
• PharmaLogic
• Eckert & Ziegler
• AtomVie
• Eczacıbaşı-Monrol
• Cardinal Health
• Nucleus RadioPharma
• Seibersdorf Labor GmbH
• Global Medical Solutions
• SOFIE
• SpectronRx
• Agilera Pharma AS
• Siemens Healthineers
• Grupo RPH
• Almac Group
• Medi-Radiopharma
• Itm Radiopharma
• Nihon Medi-Physics Co., Ltd.
• IONETIX Corporation
• GBI
• DuchemBio, Co., Ltd

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-03

Recent Developments:
• In February 2024, the clinical-stage radiopharmaceutical company Evergreen Theragnostics, Inc. announced that it has partnered and licensed with the Medical University of Innsbruck, a preeminent European research institution, to promote the development of innovative radiopharmaceuticals.
• In February 2025, Lantheus Holdings, Inc. announced a definitive agreement to acquire Evergreen Theragnostics, Inc. ("Evergreen") in an all-cash transaction that includes a $250 million upfront payment and up to an additional $752.5 million in potential milestone payments. The company is dedicated to helping clinicians Find, Fight, and Follow disease to improve patient outcomes.
• In October 2024, Atley Solutions delivered and installed the first commercial unit at Minerva Imaging's facilities in Denmark, following the regulatory approval and launch of the world's first commercial module for making Astatine-211 (At-211) radiopharmaceuticals. With the release of the Atley C100, Atley Solutions has achieved a major technical and business milestone, solidifying its position as a world leader in commercial products and services for At-211 radiopharmaceuticals.

Radiopharmaceutical CDMO/CMO Services Market Dynamics
Market Drivers: Technological Innovation
The expansion of the radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) services market is primarily fueled by ongoing technological advancements. Progress in artificial intelligence (AI)-driven imaging, automated radiopharmaceutical production, and innovations in nuclear medicine are enhancing the precision, efficiency, and clinical effectiveness of therapeutic interventions.

Further growth is supported by developments in drug formulation, the introduction of novel radioisotopes, and the emergence of personalized radiotherapies, all of which contribute to improved patient outcomes. In parallel, enhancements in quality assurance, regulatory compliance, and radiopharmaceutical synthesis processes are streamlining production workflows, thereby underpinning sustained market growth.

Challenges: Elevated Operational Expenditures
Market development is constrained by the substantial operational costs associated with radiopharmaceutical CDMO/CMO services. High expenditures arise from specialized raw materials, complex production processes, and stringent regulatory compliance requirements. The short half-life of radioisotopes necessitates advanced logistics, while the need for purpose-built facilities, trained personnel, rigorous radiation safety measures, and comprehensive quality control protocols further increases operational overheads. Collectively, these factors limit scalability and accessibility, posing challenges to broader market adoption.

Regional Outlook: North America
North America is anticipated to maintain a leading position in the radiopharmaceutical CDMO/CMO services market, demonstrating the highest compound annual growth rate (CAGR) over the forecast period. This growth is driven by increasing demand for nuclear medicine, a rising prevalence of cancer and cardiovascular disorders, and significant investments in research and development within the radiopharmaceutical sector. The region benefits from a well-established healthcare infrastructure, clear regulatory frameworks, and strong government support. Additionally, the presence of major pharmaceutical companies, specialized CDMOs, and ongoing innovations in targeted radiotherapies are expected to reinforce and accelerate market expansion in North America.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2472

Segmentation of Radiopharmaceutical CDMO/CMO Services Market-
By Application-
• Diagnostic Radiopharmaceuticals
• Therapeutic Radiopharmaceuticals
By Type of Radioisotope-
• Technetium-99m
• Fluorine-18
• Leutetium-177
• Gallium-68
• Actinium-225
• Others
By Source of Manufacturing-
• Nuclear Reactors
• Cyclotrons
By Scale of Operation-
• Preclinical
• Clinical
• Commercial
By Therapeutic Area-
• Cardiovascular Disorders
• Neurological Disorders
• Oncological Disorders
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/radiopharmaceutical-cdmocmo-services-market/2472

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.